סרטיקן ® 0.25 מ"ג טבליות מסיסות

Land: Israel

Sprache: Hebräisch

Quelle: Ministry of Health

Wirkstoff:

EVEROLIMUS 0.25 MG

Verfügbar ab:

NOVARTIS PHARMA SERVICES AG

ATC-Code:

L04AA18

Darreichungsform:

TABLETS DISPERSIBLE

Verabreichungsweg:

PER OS

Hergestellt von:

NOVARTIS PHARMA STEIN AG, SWITZERLAND

Therapiegruppe:

EVEROLIMUS

Anwendungsgebiete:

Kidney and heart transplantationCertican® is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. In kidney and heart transplantation, Certican should be used in combination with ciclosporin for microemulsion and corticosteroids.Liver transplantationCertican is indicated for the prophylaxis of organ rejection in patients receiving a hepatic transplant. In liver transplantation, Certican should be used in combination with tacrolimus and corticosteroids.

Berechtigungsdatum:

2010-02-01